InterMune Announces Proposed Public Offering of Common Stock
Sep 18, 2007 16:01:00 (ET)
BRISBANE, Calif., Sept 18, 2007 /PRNewswire-FirstCall via COMTEX/ -- InterMune, Inc. (ITMN, Trade ) today announced that it plans to offer, subject to market and other conditions, 3,000,000 shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock in connection with the offering. All of the shares in the offering will be sold by InterMune.
Goldman, Sachs & Co. is acting as the sole book-running manager of the offering. Deutsche Bank Securities Inc. will act as co-lead manager and CIBC World Markets Corp. will act as co-manager of the offering.
These shares will be issued pursuant to an effective shelf registration statement. This press release does not constitute an offer to sell or a solicitation of an offer to buy nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, if at all, will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Printed copies of the preliminary prospectus supplement and base prospectus relating to the offering may be obtained, when available, from Goldman, Sachs & Co. (Attn: Prospectus Department, 85 Broad Street, New York, New York 10004, Fax: 212-902-9316 or Email at prospectus-ny@ny.email.gs.com). InterMune intends to file a prospectus supplement relating to the offering with the SEC, which will be available along with the base prospectus filed with the SEC in connection with the shelf registration, on the SEC's website at sec.gov .
About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.
<snip> |
